Market Share Reaches Approximately 29%
Dongwha Pharmaceutical announced on December 22 that its cold medicine "Pancol S" has achieved the No. 1 sales position in the cold medicine market for three consecutive years.
According to IQVIA's third-quarter MAT (Moving Annual Total) data for 2025, Pancol S by Dongwha Pharmaceutical recorded sales of 38 billion KRW, capturing approximately 29% of the cold medicine market share.
A Dongwha Pharmaceutical representative stated, "Pancol S remains a leading cold medicine that has been consistently loved for over 50 years since its launch. We will continue to strengthen the quality and safety of our products to lead the cold medicine market going forward."
"Pancol," first launched by Dongwha Pharmaceutical in 1968, is a cold medicine containing acetaminophen, which provides antipyretic and analgesic effects. Responding to customer needs, the Pancol lineup has expanded to include four products: "Pancol S," an adult cold medicine sold in pharmacies; "Pancol iCold Syrup," a cold medicine for children; "Pancol A," an over-the-counter cold medicine available at convenience stores; and the newly launched "Pancol H," a tea-type cold medicine introduced this year.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
